Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022267856> ?p ?o ?g. }
- W2022267856 endingPage "1483" @default.
- W2022267856 startingPage "1478" @default.
- W2022267856 abstract "No AccessJournal of UrologyInvestigative Urology1 Apr 2011Paclitaxel Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy Ze Lu, Teng-Kuang Yeh, Jie Wang, Ling Chen, Greg Lyness, Yan Xin, M. Guillaume Wientjes, Valerie Bergdall, Guillermo Couto, Francisco Alvarez-Berger, Carrie E. Kosarek, and Jessie L.-S. Au Ze LuZe Lu Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio Financial interest and/or other relationship with Optimum Therapeutics. More articles by this author , Teng-Kuang YehTeng-Kuang Yeh Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio More articles by this author , Jie WangJie Wang Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio Financial interest and/or other relationship with Optimum Therapeutics. More articles by this author , Ling ChenLing Chen Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio More articles by this author , Greg LynessGreg Lyness Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio More articles by this author , Yan XinYan Xin Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio More articles by this author , M. Guillaume WientjesM. Guillaume Wientjes Colleges of Pharmacy, Ohio State University, Columbus, Ohio Financial interest and/or other relationship with Optimum Therapeutics. More articles by this author , Valerie BergdallValerie Bergdall Veterinary Medicine, Ohio State University, Columbus, Ohio More articles by this author , Guillermo CoutoGuillermo Couto Veterinary Medicine, Ohio State University, Columbus, Ohio More articles by this author , Francisco Alvarez-BergerFrancisco Alvarez-Berger Veterinary Medicine, Ohio State University, Columbus, Ohio More articles by this author , Carrie E. KosarekCarrie E. Kosarek Veterinary Medicine, Ohio State University, Columbus, Ohio More articles by this author , and Jessie L.-S. AuJessie L.-S. Au Colleges of Pharmacy, Ohio State University, Columbus, Ohio Financial interest and/or other relationship with Optimum Therapeutics. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.11.091AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We have noted that inadequate drug delivery to tumor cells is a major cause of failed intravesical therapy for nonmuscle invading bladder cancer, partly due to the dilution of drug concentration by urine production during treatment. To address this problem we developed gelatin nanoparticles of paclitaxel designed to yield constant drug concentrations. The hypothesis that a constant, therapeutic concentration in urine, bladder tissue and tumors can be attained was evaluated in dogs. Materials and Methods: We studied drug release from paclitaxel gelatin nanoparticles in culture medium in vitro. In vivo studies were performed in tumor-free dogs and in pet dogs with naturally occurring transitional cell carcinoma, in which the pharmacokinetics of paclitaxel gelatin nanoparticles were determined in plasma, urine and tumors. Results: Paclitaxel release from paclitaxel gelatin nanoparticles in vitro and in vivo was rate limited by the drug solubility in aqueous medium. This property yielded constant drug concentrations independent of changes in urine volume during the 2-hour treatment. Intravesical paclitaxel gelatin nanoparticles showed low systemic absorption, and favorable bladder tissue/tumor targeting and retention properties with pharmacologically active concentrations retained in tumors for at least 1 week. Conclusions: Constant drug release from paclitaxel gelatin nanoparticles may overcome the problem of drug dilution by newly produced urine and the sustained drug levels in tumors may decrease treatment frequency. References 1 : Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS): The American Urological Association . J Urol1999; 162: 1697. Link, Google Scholar 2 : A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharmacol Res1991; 8: 168. Google Scholar 3 : Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res1991; 51: 4347. Google Scholar 4 : Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res1991; 51: 5144. Google Scholar 5 : Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol2008; 180: 520. Link, Google Scholar 6 : Words of wisdom. Re: predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the Surveillance, Epidemiology and End Results Programme (SEER) 2003 Patterns of Care Project Eur Urol2008; 54: 1443. Google Scholar 7 : In vitro investigations of new therapeutic agents on bladder tumor cell lines. Urol Res1997; 25: 247. Google Scholar 8 : Preliminary experience with paclitaxel in advanced bladder cancer. Semin Oncol1995; 22: 1. Google Scholar 9 : Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol1997; 40: 285. Google Scholar 10 : Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther2000; 293: 761. Google Scholar 11 : p53 and treatment of bladder cancer. Nature1997; 385: 123. Google Scholar 12 : Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med1995; 1: 506. Google Scholar 13 : Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol1999; 44: 241. Google Scholar 14 : Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res2003; 9: 363. Google Scholar 15 : Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res2004; 10: 7677. Google Scholar 16 : Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharmacol Res2007; 24: 1691. Google Scholar 17 : Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol1994; 6: 465. Google Scholar 18 : Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle cremophor EL. Cancer Res1996; 56: 2112. Google Scholar 19 : An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. Int J Pharmacol2003; 250: 45. Google Scholar 20 : Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials2008; 29: 1233. Google Scholar 21 : Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res2005; 11: 4136. Google Scholar 22 : Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol1993; 11: 2127. Google Scholar 23 : Solid-state characterization of paclitaxel. J Pharmacol Sci1997; 86: 1458. Google Scholar 24 : Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther1999; 290: 871. Google Scholar 25 : Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res1998; 4: 139. Google Scholar 26 : Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res2006; 12: 1317. Google Scholar 27 : Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol1997; 41: 69. Google Scholar 28 : Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst2001; 93: 597. Google Scholar 29 : Optimized intravesical mitomycin C treatment for superficial bladder cancer: long-term follow-up. J Urol2006; 175: 268. Link, Google Scholar © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4April 2011Page: 1478-1483 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Keywordsdogstransitional cellpaclitaxelcarcinomananoparticlesurinary bladderMetricsAuthor Information Ze Lu Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio Financial interest and/or other relationship with Optimum Therapeutics. More articles by this author Teng-Kuang Yeh Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio More articles by this author Jie Wang Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio Financial interest and/or other relationship with Optimum Therapeutics. More articles by this author Ling Chen Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio More articles by this author Greg Lyness Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio More articles by this author Yan Xin Optimum Therapeutics, L. L. C., Ohio State University, Columbus, Ohio More articles by this author M. Guillaume Wientjes Colleges of Pharmacy, Ohio State University, Columbus, Ohio Financial interest and/or other relationship with Optimum Therapeutics. More articles by this author Valerie Bergdall Veterinary Medicine, Ohio State University, Columbus, Ohio More articles by this author Guillermo Couto Veterinary Medicine, Ohio State University, Columbus, Ohio More articles by this author Francisco Alvarez-Berger Veterinary Medicine, Ohio State University, Columbus, Ohio More articles by this author Carrie E. Kosarek Veterinary Medicine, Ohio State University, Columbus, Ohio More articles by this author Jessie L.-S. Au Colleges of Pharmacy, Ohio State University, Columbus, Ohio Financial interest and/or other relationship with Optimum Therapeutics. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
- W2022267856 created "2016-06-24" @default.
- W2022267856 creator A5034105070 @default.
- W2022267856 creator A5044475779 @default.
- W2022267856 creator A5050522883 @default.
- W2022267856 creator A5055001061 @default.
- W2022267856 creator A5057762207 @default.
- W2022267856 creator A5065206675 @default.
- W2022267856 creator A5073120737 @default.
- W2022267856 creator A5075877965 @default.
- W2022267856 creator A5075999518 @default.
- W2022267856 creator A5077645346 @default.
- W2022267856 creator A5080936191 @default.
- W2022267856 creator A5085031128 @default.
- W2022267856 date "2011-04-01" @default.
- W2022267856 modified "2023-10-15" @default.
- W2022267856 title "Paclitaxel Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy" @default.
- W2022267856 cites W180777263 @default.
- W2022267856 cites W1967513395 @default.
- W2022267856 cites W1974189322 @default.
- W2022267856 cites W1977413122 @default.
- W2022267856 cites W2024613014 @default.
- W2022267856 cites W2033311505 @default.
- W2022267856 cites W2040444575 @default.
- W2022267856 cites W2048120028 @default.
- W2022267856 cites W2051820513 @default.
- W2022267856 cites W2063292479 @default.
- W2022267856 cites W2066522045 @default.
- W2022267856 cites W2090075420 @default.
- W2022267856 cites W2094301465 @default.
- W2022267856 cites W2100508256 @default.
- W2022267856 cites W2144536924 @default.
- W2022267856 cites W2165982968 @default.
- W2022267856 cites W2169366755 @default.
- W2022267856 cites W2793132600 @default.
- W2022267856 cites W4327766728 @default.
- W2022267856 cites W69052102 @default.
- W2022267856 doi "https://doi.org/10.1016/j.juro.2010.11.091" @default.
- W2022267856 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3655418" @default.
- W2022267856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21334664" @default.
- W2022267856 hasPublicationYear "2011" @default.
- W2022267856 type Work @default.
- W2022267856 sameAs 2022267856 @default.
- W2022267856 citedByCount "56" @default.
- W2022267856 countsByYear W20222678562012 @default.
- W2022267856 countsByYear W20222678562013 @default.
- W2022267856 countsByYear W20222678562014 @default.
- W2022267856 countsByYear W20222678562015 @default.
- W2022267856 countsByYear W20222678562016 @default.
- W2022267856 countsByYear W20222678562017 @default.
- W2022267856 countsByYear W20222678562018 @default.
- W2022267856 countsByYear W20222678562019 @default.
- W2022267856 countsByYear W20222678562020 @default.
- W2022267856 countsByYear W20222678562021 @default.
- W2022267856 countsByYear W20222678562022 @default.
- W2022267856 countsByYear W20222678562023 @default.
- W2022267856 crossrefType "journal-article" @default.
- W2022267856 hasAuthorship W2022267856A5034105070 @default.
- W2022267856 hasAuthorship W2022267856A5044475779 @default.
- W2022267856 hasAuthorship W2022267856A5050522883 @default.
- W2022267856 hasAuthorship W2022267856A5055001061 @default.
- W2022267856 hasAuthorship W2022267856A5057762207 @default.
- W2022267856 hasAuthorship W2022267856A5065206675 @default.
- W2022267856 hasAuthorship W2022267856A5073120737 @default.
- W2022267856 hasAuthorship W2022267856A5075877965 @default.
- W2022267856 hasAuthorship W2022267856A5075999518 @default.
- W2022267856 hasAuthorship W2022267856A5077645346 @default.
- W2022267856 hasAuthorship W2022267856A5080936191 @default.
- W2022267856 hasAuthorship W2022267856A5085031128 @default.
- W2022267856 hasBestOaLocation W20222678562 @default.
- W2022267856 hasConcept C121608353 @default.
- W2022267856 hasConcept C126322002 @default.
- W2022267856 hasConcept C126894567 @default.
- W2022267856 hasConcept C143998085 @default.
- W2022267856 hasConcept C185592680 @default.
- W2022267856 hasConcept C2777292972 @default.
- W2022267856 hasConcept C2778823387 @default.
- W2022267856 hasConcept C2780352672 @default.
- W2022267856 hasConcept C55493867 @default.
- W2022267856 hasConcept C71924100 @default.
- W2022267856 hasConceptScore W2022267856C121608353 @default.
- W2022267856 hasConceptScore W2022267856C126322002 @default.
- W2022267856 hasConceptScore W2022267856C126894567 @default.
- W2022267856 hasConceptScore W2022267856C143998085 @default.
- W2022267856 hasConceptScore W2022267856C185592680 @default.
- W2022267856 hasConceptScore W2022267856C2777292972 @default.
- W2022267856 hasConceptScore W2022267856C2778823387 @default.
- W2022267856 hasConceptScore W2022267856C2780352672 @default.
- W2022267856 hasConceptScore W2022267856C55493867 @default.
- W2022267856 hasConceptScore W2022267856C71924100 @default.
- W2022267856 hasIssue "4" @default.
- W2022267856 hasLocation W20222678561 @default.
- W2022267856 hasLocation W20222678562 @default.
- W2022267856 hasLocation W20222678563 @default.
- W2022267856 hasLocation W20222678564 @default.
- W2022267856 hasOpenAccess W2022267856 @default.
- W2022267856 hasPrimaryLocation W20222678561 @default.
- W2022267856 hasRelatedWork W1979321249 @default.